The number of patients who require maintenance on anticoagulation therapy (warfarin/Coumadin ®) for minimizing risk of cardiovascular events like stroke or thromboembolism is increasing.

Antiplatelets are particularly beneficial for people who have had a previous heart attack or stroke, those with CAD, or ...

According to US secondary stroke prevention guidelines, patients with ESUS should not be treated with anticoagulants or ...

Classic anticoagulants such as heparin often cannot ... and coagulation processes and should be reviewed for their ...

In the high-risk subgroup of patient with DDAF and vascular disease, anticoagulation therapy appears to reduce thromboembolic events with a greater magnitude than in patients without vascular disease.

Heparin bridging during the resumption of anticoagulation post-intracranial hemorrhage may be linked to an increased risk for bleeding.

Brazilian researchers from UFRJ and INBEB uncover how mutant p53, a key tumor suppressor, transforms proteins like p63 and ...

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a new ...

PONTE VEDRA, Fla., Aug. 20, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next ...

Patients with atrial fibrillation are at high risk for stroke, and international guidelines recommend oral anticoagulant therapy. In patients with stable vascular disease without atrial ...